Filing identity and reporting period
Important mismatch: The supplied filing is for Oncobiologics, Inc., not Outlook Therapeutics, Inc. It is a Form 10-K for the fiscal year ended September 30, 2016, not a quarterly report for “2016 Q4.” The summary below reflects the filing provided.
Business context
Oncobiologics was a clinical-stage biosimilar developer focused on monoclonal antibodies in immunology and oncology. It reported eight candidates: ONS-3010 (adalimumab/Humira) and ONS-1045 (bevacizumab/Avastin) had completed Phase 1 trials and were being prepared for Phase 3; six candidates remained preclinical. The company had no approved products and no product-sales revenue.
Financial results and liquidity
| Metric | FY ended Sep. 30, 2016 | FY ended Sep. 30, 2015 |
|---|---|---|
| Collaboration revenue | $3.0 million | $5.2 million |
| Research and development expense | $33.1 million | $38.9 million |
| General and administrative expense | $21.6 million | $12.9 million |
| Loss from operations | $51.8 million | $46.6 million |
| Interest expense | $1.5 million | $2.3 million |
| Net loss | $53.3 million | $48.7 million |
| Net cash used in operating activities | $45.5 million | $27.5 million |
| Net cash used in investing activities | $1.1 million | $8.8 million |
| Net cash provided by financing activities | $39.9 million | $43.0 million |
At September 30, 2016, cash was $2.35 million, total current assets were $5.68 million, current liabilities were $20.44 million, and accumulated deficit was $147.4 million. Current liabilities therefore exceeded current assets by about $14.8 million. The company had $4.6 million of stockholder notes payable on demand, in addition to bank/equipment debt and capital lease obligations. Product margins were not applicable because there were no product sales.
Material changes versus the prior year
- Collaboration revenue declined $2.24 million, or about 43%, mainly because of lower milestone and research-and-development payments.
- R&D expense fell $5.77 million, primarily as ONS-1045 spending decreased while the company sought a partner to share Phase 3 costs; ONS-3010 spending increased as Phase 3 preparations advanced.
- G&A expense rose $8.73 million, including higher stock-based compensation associated with the IPO, a CEO bonus triggered by the IPO, and public-company compliance costs.
- Net loss widened by $4.66 million. Operating cash use increased by $18.01 million.
- The May 2016 IPO and concurrent private placement generated approximately $33.8 million in net proceeds. Year-end cash nevertheless fell from $9.07 million to $2.35 million.
Outlook, risks, and unusual items
- Management said year-end cash plus proceeds from post-year-end note and warrant financing was expected to fund operations only through February 2017. It anticipated needing substantial additional capital and warned that failure to secure financing or partnerships could force delays, reduced activity, or program holds.
- Auditors expressed substantial doubt about the company’s ability to continue as a going concern. The financial statements were prepared on a going-concern basis without adjustments for the outcome of that uncertainty.
- After year-end, the company raised $8.35 million in senior secured notes, including exchange of $1.85 million of bridge notes; it used $2.4 million to repay senior bank loans. The notes carried 5% interest, matured in December 2017, and were secured by company assets, including intellectual property. Additional note issuance was permitted under the agreement.
- ONS-3010 Phase 3 enrollment was planned for 2017, subject to additional funding. ONS-1045 Phase 3 depended on obtaining a development partner or additional funding. Both candidates had met their Phase 1 primary and secondary endpoints, but these results did not establish regulatory approval or commercial success.
- For ONS-3010, Huahai could retain 51% value ownership if it funded its share of later development costs; Oncobiologics’ corresponding interest would be 49%. The company had not exercised its option to reacquire the rights.
- Key risks include financing and dilution, clinical and regulatory failure or delay, biosimilarity and interchangeability requirements, patent litigation, competition, manufacturing scale-up, reliance on partners, and uncertain reimbursement and market adoption.
Most important facts for investors to verify
- Confirm the intended issuer and period: this filing is Oncobiologics’ FY2016 10-K, not an Outlook Therapeutics filing or a quarterly report.
- Verify current liquidity, cash runway, debt balances and terms, including the subsequent secured financing and its collateral and covenants.
- Check whether additional financing or licensing/co-development agreements were completed and whether the stated February 2017 runway was extended.
- Track Phase 3 initiation, funding, regulatory feedback, trial results, and Huahai’s funding and ownership position for ONS-3010.
- Assess the drivers of rising losses and cash burn, and the potential dilution from equity, warrants and equity compensation.